MassARRAY assay: A more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders [12]

Leukemia

Volumn 22, Issue 3, 2008, Pages 660-663

  Fu, J F ^a   Shi, J Y ^a   Zhao, W L ^a   Li, G ^a   Pan, Q ^a   Li, J M ^a   Hu, J ^a   Shen, Z X ^a   Jin, J ^b   Chen, F Y ^c   Chen, S J ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

CHINESE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; LETTER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; RESTRICTION MAPPING; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 40749152298     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404931     Document Type: Letter

References (8)

1. Delaval B, Lelièvre H, Birnbaum D. Myeloproliferative disorders: The centrosome connection. Leukemia 2005; 19: 1739-1744.
2. Shi JY, Shi ZZ, Zhang ZJ, Zhu YM, Gu BW, Li G et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004; 14: 759-768.
3. Cantor CR, Campbell PJ, Scott LM, Buck G, Wheatley K, East CL et al Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
4. James C, Delhommeau F, Marzac C, Teyssandier I, Couedic JP, Giraudier S et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162-2168.
6. Nussenzveig RH, Swierczek SI, Jelinek J, Gaikwad A, Enli L, Verstovsek S et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32-38.
7. Sattler M, Walz C, Crowley BJ, Lengfelder E, Janne PA, Rogers AM et al. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood 2006; 107: 1237-1238.
8. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006; 108: 1652-1660.